The anti-tumour effect of dual BET/EGFR inhibition is also significant in a series of other types of cancer, including luminal/HER2+ breast cancer, gastric cancer, pancreatic cancer, ovarian cancer and chronic myelogenous leukaemia, reflecting its great potential value in cancer treatment. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.